Group Psychotherapy of Dysfunctional Fear of Progression in Patients with Chronic Arthritis or Cancer
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Background: This study investigated the effectiveness of brief psychotherapeutic group interventions in reducing dysfunctional fear of disease progression (FoP). The interventions comprised either cognitive-behavioral group therapy or supportive-experiential group therapy. We tested whether these generic interventions would prove effective in different illness types. Methods: Chronic arthritis in- patients (n = 174) and cancer in-patients (n = 174), respectively, were randomized to receive one of the two interventions. The patients provided data before intervention, at discharge, and at 3 and 12 months of follow-up. FoP was the primary outcome, secondary outcomes were anxiety, depression and quality of life. A treatment-as-usual control group provided data on the primary outcome. Results: Patients with chronic arthritis indicated higher levels of FoP than cancer patients. The results revealed that, compared with no specialized intervention, both group therapies were effective in reducing dysfunctional FoP, but only among cancer patients. The effect sizes were 0.54 (cognitive-behavioral therapy) and 0.50 (supportive experiential therapy). The interventions were not differently effective in reducing the secondary outcomes. Conclusions: Dysfunctional FoP can be effectively targeted with brief group interventions. Psychotherapeutic interventions for reducing FoP should focus on specific illness characteristics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among limited studies, most of them focused on Cognitive Behavioral Therapy (CBT)'s efficacy, showing low to moderate effectsizes.[9][10][11]”
From A randomized clinical trial: Efficacy of group-based acceptance and commitment therapy program for breast cancer patients with high fear of progression (2024) · cites this paper as [9]
In the citing paper
“ConquerFear participants had clinically and statistically greater improvements than control participants from baseline to immediately post-intervention on Fear of Cancer Inventory (FCRI) scores (P < .001)and most secondary outcomes; differences on FCRI scores were maintained at 3-and 6-months follow-up.”
From Psychological intervention (ConquerFear) for treating fear of cancer recurrence: mediators and moderators of treatment efficacy (2019) · cites this paper as [5]
In the citing paper
“randomized trials have shown that they significantly reduce fear of cancer recurrence relative to usual care [33], relaxation training [34], and supportive-expressive group therapy [29, 31].”
In the citing paper
“The few prior anxiety-related interventions have focused on fear of recurrence [29–31] or uncertainty in later survivorship phases [32].”
Citations
Cites
Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis
Barth, J., Schumacher, M., & Herrmann-Lingen, C. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000146332.53619.b2 · Cited by 1,358 · cited 1×
“Research has shown that many medical patients suffer from comorbid mental illness [”
BackgroundSF-36, Fragebogen zum Gesundheitszustand
Bullinger, M., & Kirchberger, I. (1998) · Cited by 835
Alonso, J., Ferrer, M., Gandek, B., Ware, J. E., Aaronson, N. K., Mosconi, P., Rasmussen, N. K., Bullinger, M., Fukuhara, S., Kaasa, S., et al. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000018472.46236.05 · Cited by 786 · cited 1×
“Although there are also differences in consequences [”
BackgroundWhich chronic conditions are associated with better or poorer quality of life?
Sprangers, M. A. G., de Regt, E. B., Andries, F., van Agt, H. M. E., Bijl, R. V., de Boer, J. B., Foets, M., Hoeymans, N., Jacobs, A. E., Kempen, G. I. J. M., et al. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00204-3 · Cited by 642
Newell, S. A. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.8.558 · Cited by 591
Saarni, S. I., Härkänen, T., Sintonen, H., Suvisaari, J., Koskinen, S., Aromaa, A., & Lönnqvist, J. (2006) · Quality of Life Research · doi:10.1007/s11136-006-0020-1 · Cited by 412
Mehnert, A., & Koch, U. (2007) · Psycho-Oncology · doi:10.1002/pon.1057 · Cited by 402
Kissane, D. W., Grabsch, B., Clarke, D. M., Smith, G. C., Love, A. W., Bloch, S., Snyder, R. D., & Li, Y. (2007) · Psycho-Oncology · doi:10.1002/pon.1185 · Cited by 376
Nezu, A. M., Nezu, C. M., Felgoise, S. H., McClure, K. S., & Houts, P. S. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.6.1036 · Cited by 323
Henrich, G., & Herschbach, P. (2000) · European Journal of Psychological Assessment · doi:10.1027//1015-5759.16.3.150 · Cited by 321 · cited 1×
“Two components, physical and mental, are computed with scores ranging from 0 (worst) to 100 (best). The patients reported on their HRQoL during the past 2 weeks.Life satisfaction was measured with the Questions on Life Satisfaction (FLZ M ) [”
MethodSelf-citation
Research works printed but not linked: 3
- 10.1002%2F%28SICI%291099-1611%28199706%296%3A2%3C95%3A%3AAID-PON250%3E3.0.CO%3B2-B · doi:10.1002/(sici)1099-1611(199706)6:2<95::aid-pon250>3.0.co;2-b
- 10.1111%2Fj.1440-1614.2006.01795.x · DOI
- 10.1002%2F%28SICI%291099-1611%28199703%296%3A1%3C25%3A%3AAID-PON240%3E3.3.CO%3B2-E · doi:10.1002/(sici)1099-1611(199703)6:1<25::aid-pon240>3.3.co;2-e
Cited by
Koch, L., Jansen, L., Brenner, H., & Arndt, V. (2013) · Psycho-Oncology · doi:10.1002/pon.3022 · Cited by 511
“Already existing interventions have been shown to reduce FoR [51,59], but more research is needed to support and evaluate effectiveness of interventions targeting FoR and shed light on possible therapeutic mechanisms.”
BackgroundFear of cancer recurrence: a systematic literature review of self‐report measures
Thewes, B., Butow, P., Zachariae, R., Christensen, S., Simard, S., & Gotay, C. (2012) · Psycho-Oncology · doi:10.1002/pon.2070 · Cited by 262
“Sensitivity to change was supported by the results of a randomised controlled trial aimed at reducing dysfunctional fear of progression [64,65].”
ResultKoch, L., Bertram, H., Eberle, A., Holleczek, B., Schmid-Höpfner, S., Waldmann, A., Zeissig, S. R., Brenner, H., & Arndt, V. (2014) · Psycho-Oncology · doi:10.1002/pon.3452 · Cited by 253
Does fear of cancer recurrence predict cancer survivors' health care use?
Lebel, S., Tomei, C., Feldstain, A., Beattie, S., & McCallum, M. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-012-1685-3 · Cited by 211
Lebel, S., Mutsaers, B., Tomei, C., Leclair, C. S., Jones, G., Petricone-Westwood, D., Rutkowski, N., Ta, V., Trudel, G., Laflamme, S. Z., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0234124 · Cited by 203
“It seems that the differences in labels (e.g. HA, FoP, FoH), in perspectives (broad vs. narrow), and potentially in professional identities (e.g., psychiatry, psychosomatic medicine, behavioral medicine, clinical health psychology, psycho-oncology) have precluded a unified conceptual view on realistic fears and worrie…”
BackgroundInfluentialSelf-citationFear of cancer recurrence and death anxiety
Sharpe, L., Curran, L., Butow, P., & Thewes, B. (2018) · Psycho-Oncology · doi:10.1002/pon.4783 · Cited by 149
“The first trial randomised patients with either cancer or rheumatoid arthritis to receive cognitive‐behaviour therapy or expressive supportive psychotherapy or a control.(66) This trial found both group interventions to be equally efficacious for cancer patients; both resulted in reductions in fear of cancer progressi…”
BackgroundEvaluation of two group therapies to reduce fear of progression in cancer patients
Herschbach, P., Book, K., Dinkel, A., Berg, P., Waadt, S., Duran, G., Engst-Hastreiter, U., & Henrich, G. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-009-0696-1 · Cited by 145
“Based on this background, we conducted a study to evaluate the effects of two different short psychotherapeutic group interventions in reducing FoP in patients with cancer [18].”
MethodSelf-citationYoung and worried: Age and fear of recurrence in breast cancer survivors.
Lebel, S., Beattie, S., Arès, I., & Bielajew, C. (2013) · Health Psychology · doi:10.1037/a0030186 · Cited by 143
Herschbach, P., & Dinkel, A. (2013) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-40187-9_2 · Cited by 169
“The effect size were 0.54 for the CBT intervention, 0.50 for the SET intervention, and 0.14 for the TAU group (Herschbach et al. 2010a).”
BackgroundMethodInfluentialSelf-citationFear of cancer recurrence in colorectal cancer survivors
Custers, J. A. E., Gielissen, M. F. M., Janssen, S. H. V., de Wilt, J. H. W., & Prins, J. B. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-015-2808-4 · Cited by 141
Mehnert, A., Koch, U., Sundermann, C., & Dinkel, A. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.765063 · Cited by 132
Self-citationLebel, S., Maheu, C., Lefebvre, M., Secord, S., Courbasson, C., Singh, M., Jolicoeur, L., Benea, A., Harris, C., Fung, M. F. K., et al. (2014) · Journal of Cancer Survivorship · doi:10.1007/s11764-014-0357-3 · Cited by 127
“To date, there has been only one published group intervention study that has addressed fear of disease progression, a concept related to FCR, in people with cancer or chronic arthritis [19].”
BackgroundDieng, M., Butow, P. N., Costa, D. S. J., Morton, R. L., Menzies, S. W., Mireskandari, S., Tesson, S., Mann, G. J., Cust, A. E., & Kasparian, N. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2278 · Cited by 123
Fear of Progression in Cancer Patients and Survivors
Dinkel, A., & Herschbach, P. (2018) · Recent Results in Cancer Research · doi:10.1007/978-3-319-64310-6_2 · Cited by 114
Self-citationGlobal quality of life in breast cancer: systematic review and meta-analysis
Biparva, A. J., Raoofi, S., Rafiei, S., Kan, F. P., Kazerooni, M., Bagheribayati, F., Masoumi, M., Doustmehraban, M., Sanaei, M., Zarabi, F., et al. (2022) · BMJ Supportive & Palliative Care · doi:10.1136/bmjspcare-2022-003642 · Cited by 135
“Many factors have been affirmed to affect the QoL of patients with BC. 9–15 There are several useful articles reporting the status of QoL of patients with BC along with its associated factors.”
BackgroundSun, H., Yang, Y., Zhang, J., Liu, T., Wang, H., Garg, S., & Zhang, B. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s202432 · Cited by 119
“Other reasons could be the lack of consen- sus in standard definition of clinical or dysfunctional FCR and insufficient efforts made to establish the same clinical cut-offs for FCR.”
BackgroundInfluentialThewes, B., Lebel, S., Seguin Leclair, C., & Butow, P. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-015-3025-x · Cited by 104
“Some of these treatments use verbal and/or written exposure to the worst fear as part of the treatment plan [26, 27].”
BackgroundSarkar, S., Scherwath, A., Schirmer, L., Schulz-Kindermann, F., Neumann, K., Kruse, M., Dinkel, A., Kunze, S., Balck, F., Kröger, N., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.139 · Cited by 102
Self-citationHinz, A., Mehnert-Theuerkauf, A., Ernst, J., Herschbach, P., & Schulte, T. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2516-5 · Cited by 123
Self-citationEmpirical validation of the English version of the Fear of Cancer Recurrence Inventory
Lebel, S., Simard, S., Harris, C., Feldstain, A., Beattie, S., McCallum, M., Lefebvre, M., Savard, J., & Devins, G. M. (2016) · Quality of Life Research · doi:10.1007/s11136-015-1088-2 · Cited by 90
Curran, L., Sharpe, L., MacCann, C., & Butow, P. (2020) · Journal of Behavioral Medicine · doi:10.1007/s10865-019-00129-x · Cited by 82
Fear of Progression in Partners of Chronically Ill Patients
Zimmermann, T., Herschbach, P., Wessarges, M., & Heinrichs, N. (2011) · Behavioral Medicine · doi:10.1080/08964289.2011.605399 · Cited by 78
“16 There is compelling empirical evidence that FoP is prevalent in the majority of patients suffering from various chronic conditions such as cancer, diabetes mellitus and rheumatism.”
BackgroundSelf-citationSelf-efficacy and fear of cancer progression during the year following diagnosis of breast cancer
Melchior, H., Büscher, C., Thorenz, A., Grochocka, A., Koch, U., & Watzke, B. (2013) · Psycho-Oncology · doi:10.1002/pon.2054 · Cited by 69
“First approaches were developed and are under evaluation [16,18].”
BackgroundMethodResultInfluentialComorbidity of fear of progression and anxiety disorders in cancer patients
Dinkel, A., Kremsreiter, K., Marten‐Mittag, B., & Lahmann, C. (2014) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2014.08.006 · Cited by 74
“Current approaches do not take into account possible consequences of comorbid anxiety disorders or other mental disorders for assessment and intervention [51–54].”
BackgroundSelf-citationHaidari, R. E., Abbas, L. A., Nerich, V., & Anota, A. (2020) · Cancers · doi:10.3390/cancers12030696 · Cited by 66
“In addition, HRQoL was found to be affected by the therapeutic procedures used [17].”
MethodAre fear of cancer recurrence and fear of progression equivalent constructs?
Coutts‐Bain, D., Sharpe, L., Pradhan, P., Russell, H., Heathcote, L. C., & Costa, D. S. J. (2022) · Psycho-Oncology · doi:10.1002/pon.5944 · Cited by 71
“Scores ≥34 indicate an elevated degree of FOP, and have been proposed as a marker of clinically significant FOP warranting treatment in clinical trials.(27,28) Both questionnaires were administered to all participants irrespective of disease status.”
BackgroundPetzel, M. Q. B., Parker, N. H., Valentine, A. D., Simard, S., Nogueras-Gonzalez, G. M., Lee, J. E., Pisters, P. W. T., Vauthey, J.-N., Fleming, J. B., & Katz, M. H. G. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2566-1 · Cited by 63
“To the extent that a short course of psychotherapy may effectively yield a long-term reduction in FCR, these data support the screening of all patients for severe FCR early in the postoperative survivorship period—even patients believed to be at relatively low risk for recurrence.(27,28) The FCRI severity subscale pro…”
Yang, Y., Sun, H., Liu, T., Zhang, J., Wang, H., Liang, W., Chen, Y., & Zhang, B. (2018) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2018.09.003 · Cited by 65
Maheu, C., Lebel, S., Courbasson, C., Lefebvre, M., Singh, M., Bernstein, L. J., Muraca, L., Benea, A., Jolicoeur, L., Harris, C., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2326-x · Cited by 59
“related to FCR, in people with cancer or chronic arthritis [31].”
BackgroundFait, K., Vilchinsky, N., Dekel, R., Levi, N., Hod, H., & Matetzky, S. (2018) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2018.02.011 · Cited by 64
“Fear of illness progression (FoP) indicates people's essentially rational fear that their disease will advance and that their condition will likely deteriorate over time [20,21].”
BackgroundFear of Cancer Recurrence in an Era of Personalized Medicine
Thewes, B., Husson, O., Poort, H., Custers, J. A. E., Butow, P. N., McLachlan, S.-A., & Prins, J. B. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.8212 · Cited by 54
High Fear of Cancer Recurrence in Chinese Newly Diagnosed Cancer Patients
Luo, X., Li, W., Yang, Y., Humphris, G., Zeng, L., Zhang, Z., Garg, S., Zhang, B., & Sun, H. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.01287 · Cited by 51
Validity of the Fear of Progression Questionnaire‐Short Form in patients with systemic sclerosis
Kwakkenbos, L., van den Hoogen, F. H. J., Custers, J., Prins, J., Vonk, M. C., van Lankveld, W. G. J. M., Becker, E. S., & van den Ende, C. H. M. (2012) · Arthritis Care & Research · doi:10.1002/acr.21618 · Cited by 50
“A recent study (17) showed that 2 short psychotherapeutic group interventions were effective in reducing fear of progression in cancer patients.”
BackgroundConquerFear Authorship group, Sharpe, L., Turner, J., Fardell, J. E., Thewes, B., Smith, A. B., Gilchrist, J., Beith, J., Girgis, A., Tesson, S., et al. (2019) · Journal of Cancer Survivorship · doi:10.1007/s11764-019-00788-4 · Cited by 46
Fear of progression in parents of childhood cancer survivors: prevalence and associated factors
Peikert, M. L., Inhestern, L., Krauth, K. A., Escherich, G., Rutkowski, S., Kandels, D., Schiekiera, L., & Bergelt, C. (2021) · Journal of Cancer Survivorship · doi:10.1007/s11764-021-01076-w · Cited by 55
Mehnert-Theuerkauf, A., Hufeld, J. M., Esser, P., Goerling, U., Hermann, M., Zimmermann, T., Reuter, H., & Ernst, J. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1125545 · Cited by 60
“We use the validated German short form of the Fear of Progression Questionnaire (FoP-Q-SF) (Mehnert et al., 2006a) to measure fear of cancer progression and recurrence in patients and relatives (Zimmermann et al., 2011).”
BackgroundInfluentialHu, X., Wang, W., Wang, Y., & Liu, K. (2020) · Psycho-Oncology · doi:10.1002/pon.5546 · Cited by 51
The Psychosomatic Assessment: Strategies to Improve Clinical Practice
(2011) · Advances in Psychosomatic Medicine · doi:10.1159/isbn.978-3-8055-9854-5 · Cited by 45
Clever, K., Schepper, F., Pletschko, T., Herschbach, P., Christiansen, H., & Martini, J. (2018) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2018.01.008 · Cited by 44
Self-citationLynch, F. A., Katona, L., Jefford, M., Smith, A. B., Shaw, J., Dhillon, H. M., Ellen, S., Phipps-Nelson, J., Lai-Kwon, J., Milne, D., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092969 · Cited by 42
“A cut-off score of 24–33 was used to suggest subthreshold levels of fear of progression [35] and a score ≥34 was used to identify participants with high levels of fear of progression [36].”
MethodFear of progression in parents of childhood cancer survivors: A dyadic data analysis
Peikert, M. L., Inhestern, L., Krauth, K. A., Escherich, G., Rutkowski, S., Kandels, D., & Bergelt, C. (2020) · Psycho-Oncology · doi:10.1002/pon.5508 · Cited by 44
Sabariego, C., Brach, M., Herschbach, P., Berg, P., & Stucki, G. (2010) · The European Journal of Health Economics · doi:10.1007/s10198-010-0266-y · Cited by 45
“While the demonstration of reduced fear of progression is an important patient-relevant outcome, it would be as important from a societal perspective to demonstrate whether CBT and SET can result in the reduction of direct and indirect medical costs.”
BackgroundInfluentialSelf-citationExploring the Relationship Between Fear of Cancer Recurrence and Sleep Quality in Cancer Survivors
Berrett-Abebe, J., Cadet, T., Pirl, W., & Lennes, I. (2015) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2015.1020586 · Cited by 35
Muldbücker, P., Steinmann, D., Christiansen, H., de Zwaan, M., & Zimmermann, T. (2020) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2020.1762823 · Cited by 38
Anxiety Disorders in Patients With Somatic Diseases
Henning, M., Subič-Wrana, C., Wiltink, J., & Beutel, M. E. (2020) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000779 · Cited by 38
“A group intervention targeting the fear of progression of the somatic diseases comparing an integration of CBT and supportive-experimental psychotherapy with treatment as usual in patients with arthritis and cancer (n = 174) found a positive effect of the intervention only in cancer patients (66).”
MethodDirkse, D., Hadjistavropoulos, H. D., Alberts, N. A., Karin, E., Schneider, L. H., Titov, N., & Dear, B. F. (2020) · Journal of Cancer Survivorship · doi:10.1007/s11764-019-00810-9 · Cited by 29
Nota, I., Drossaert, C. H. C., Taal, E., & van de Laar, M. A. F. J. (2014) · Arthritis Care & Research · doi:10.1002/acr.22531 · Cited by 32
Petricone‐Westwood, D., Jones, G., Mutsaers, B., Leclair, C. S., Tomei, C., Trudel, G., Dinkel, A., & Lebel, S. (2018) · International Journal of Behavioral Medicine · doi:10.1007/s12529-018-9748-6 · Cited by 34
Self-citationAssociation Between Daily Worry, Pathological Worry, and Fear of Progression in Patients With Cancer
Dinkel, A., Marten‐Mittag, B., & Kremsreiter, K. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.648623 · Cited by 28
“This approach has proven feasible and effective in reducing FoP of patients with cancer (Herschbach et al., 2010; Dinkel et al., 2012; Rudolph et al., 2018) and is supported by the independent association between our measures of daily worry, which focuses on the content of worrying thoughts.”
BackgroundSelf-citationPrinciples of Psychosomatic Assessment
Fava, G. A., Sonino, N., & Wise, T. N. (2011) · Advances in psychosomatic medicine · doi:10.1159/000329997 · Cited by 32
Addressing fear of recurrence: improving psychological care in cancer survivors
Tomei, C., Lebel, S., Maheu, C., & Mutsaers, B. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3103-8 · Cited by 30
“Intervention studies suggest it is possible to help cancer survivors deal with realistic FCR [4, 5].”
BackgroundReb, A. M., Borneman, T., Economou, D., Cangin, M. A., Cope, D. G., Ma, H., Ruel, N., Sharpe, L., Patel, S. K., Cristea, M., et al. (2020) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2020.101855 · Cited by 26
Pickup, B., Coutts‐Bain, D., & Todd, J. (2024) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2024.111595 · Cited by 27
Clever, K., Schepper, F., Maier, S., Christiansen, H., & Martini, J. (2019) · Family Process · doi:10.1111/famp.12480 · Cited by 27
Sharpe, L., Richmond, B., Todd, J., Dudeney, J. E., Dear, B. F., Szabó, M., Sesel, A.-L., Forrester, M., & Menzies, R. E. (2023) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2023.111514 · Cited by 27
Psychodynamic interventions in cancer care I: psychometric results of a randomized controlled trial
Ludwig, G., Krenz, S., Zdrojewski, C., Bot, M., Rousselle, I., Stagno, D., Luethi, F., Leyvraz, S., & Stiefel, F. (2013) · Psycho-Oncology · doi:10.1002/pon.3374 · Cited by 25
“Cancer patients’ willingness to accept psychological support has been estimated between 39% [5] and 91% [6], and efficacy of adjuvant psychological treatment has been demonstrated [7–13].”
BackgroundDinkel, A., Herschbach, P., Berg, P., Waadt, S., Duran, G., Engst-Hastreiter, U., Henrich, G., & Book, K. (2012) · Behavioral Medicine · doi:10.1080/08964289.2011.640364 · Cited by 24
Self-citationLi, M. C., & Cheng, H. (2020) · Psycho-Oncology · doi:10.1002/pon.5609 · Cited by 25
“A cut‐off score of ≥ 34 indicated that a participant had FCR.(25)”
BackgroundInfluentialFrangou, E., Bertelli, G., Love, S., Mackean, M., Glasspool, R. M., Fotopoulou, C., Cook, A. D., Nicum, S., Lord, R., Ferguson, M., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.05.024 · Cited by 23
Chen, R., Yang, H., Zhang, H., Chen, J., Liu, S., & Li, W. (2023) · BMC Psychology · doi:10.1186/s40359-023-01211-5 · Cited by 25
“It has demonstrated that most patients reported low or moderate level of FoP [7], and still suffer from it even years after their initial diagnosis [11].”
BackgroundSiedentopf, F., Marten‐Mittag, B., Utz-Billing, I., Schoenegg, W., Kentenich, H., & Dinkel, A. (2009) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2009.10.014 · Cited by 28
“014 feelings of vulnerability, anxiety, fear of disease progression and grief to major problems like depression, panic attacks, anxiety disorders and a substantial crisis [3,4].”
BackgroundSelf-citationArch, J. J., Mitchell, J. L., Genung, S. R., Fisher, R., Andorsky, D. J., & Stanton, A. L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5289-x · Cited by 20
Psychometric properties of the Chinese version Fear of Cancer Recurrence Questionnaire-7 (FCR-7).
Yang, Y., Humphris, G. M., Sun, H., Li, W., Hao, Y., Liu, T., Zhang, J., Wang, H., & Zhang, B. (2019) · Professional Psychology Research and Practice · doi:10.1037/pro0000257 · Cited by 22
“It evaluates the degree of depressive symptoms, and the items range from 0 to 3 (0 = not at all, and 3 = nearly everyday) (Herschbach et al., 2010).”
BackgroundInfluentialClarke, S. T., Murphy, B. M., Rogerson, M., Grande, M. R. L., Hester, R., & Jackson, A. C. (2024) · Heart and Mind · doi:10.4103/hm.hm-d-23-00046 · Cited by 22
Pradhan, P., Sharpe, L., Butow, P. N., & Russell, H. (2021) · Psycho-Oncology · doi:10.1002/pon.5748 · Cited by 20
“Thewes et al.23 reviewed measures of FCR/P and concluded that the Fear of Cancer Recurrence Inventory (FCRI) and FoP‐”
BackgroundMethodInfluentialErim, Y., Loquai, C., Schultheis, U., Lindner, M., Beckmann, M., Schadendorf, C., & Senf, W. (2013) · Oncology Research and Treatment · doi:10.1159/000355137 · Cited by 19
Does interpretation bias moderate the relationship between pain and fear of cancer recurrence?
Pradhan, P., Sharpe, L., Butow, P. N., Coutts‐Bain, D., & Heathcote, L. C. (2022) · Health Psychology · doi:10.1037/hea0001217 · Cited by 20
Folkerts, A., Haarmann, L., Nielsen, J., Saliger, J., Eschweiler, M., Karbe, H., Allert, N., Vida, V., Trenkwalder, C., Kruse, A., et al. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223314 · Cited by 22
Yang, L., Liu, J., Liu, Q., Wang, Y., Yu, J., & Qin, H. (2023) · Journal of Advanced Nursing · doi:10.1111/jan.15692 · Cited by 22
Lin, T., Ma, X., Yang, Y., Hu, X., Fu, L., & Li, J. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-077964 · Cited by 25
“The scale was developed by Zimmermann et al 21 based on the FOP- Q-SF and includes 12 items that were scored by spouses based on their fear of the patient’s disease progression; it uses a 5-point Likert scale ranging from 1 (‘not at all’) to 5 (‘always’).”
MethodMaheu, C., Lebel, S., Tomei, C., Singh, M. D., & Esplen, M. J. (2014) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2014.12.003 · Cited by 21
Heidkamp, P., Breidenbach, C., Hiltrop, K., Kowalski, C., Enders, A., Pfaff, H., Weltermann, B., Geiser, F., & Ernstmann, N. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06329-z · Cited by 20
Prediction of end-of-life fears in COPD – hoping for the best but preparing for the worst
Stenzel, N., Vaske, I., Kühl, K., Kenn, K., & Rief, W. (2015) · Psychology and Health · doi:10.1080/08870446.2015.1014816 · Cited by 20
Szalai, M., Szirmai, A., Füge, K., Makai, A., Erdélyi, G., Prémusz, V., & Bódis, J. (2017) · European Journal of Cancer Care · doi:10.1111/ecc.12656 · Cited by 19
Rudolph, B., Wünsch, A., Herschbach, P., & Dinkel, A. (2017) · PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie · doi:10.1055/s-0043-107774 · Cited by 15
“Psychother Psych Med 2018; 68: 38–43 6 Sitzungen bietet im Vergleich zu der 4-stündigen Gruppentherapie im Rehabilitationssetting, wie sie ursprünglich durchgeführt wurde [11, 12], die Möglichkeit einer intensiveren individualisierten Auseinandersetzung mit PA.”
BackgroundSelf-citationPradhan, P., Sharpe, L., Butow, P. N., Smith, A. B., & Russell, H. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.634136 · Cited by 13
“Nevertheless, results on the FoP-SF-Q in the FearLESS study were similar to our results.”
BackgroundInfluentialYang, Y., Zhang, Y., Liang, L., Liao, X., Meng, J., Cai, R., Ye, H., Hu, J., He, X., & Shi, L. (2022) · Psycho-Oncology · doi:10.1002/pon.6027 · Cited by 15
“A cut‐off of ≥34 was used to differentiate functional from dysfunctional levels of FoP.(23) Previous studies on FoP in parents of children with cancer have also used this cut‐off.”
MethodHealth‐related quality of life and fear of progression in individuals with Li‐Fraumeni syndrome
Kiermeier, S., Schott, S., Nees, J., Dutzmann, C. M., Strüwe, F. J., Kratz, C. P., Sauer, C., Fleischer, A., Keymling, M., & Maatouk, I. (2024) · Journal of Genetic Counseling · doi:10.1002/jgc4.1859 · Cited by 16
“In order to section the sample for low and high scores of FoP, regardless of cancer history, we used a cut-off previously suggested for cancer patients, with a mean of ≥34 indicating a high level of FoP (Herschbach, Berg, et al., 2010).”
Lu, Q., Liu, Q., Fang, S., Ma, Y., Zhang, B., Li, H., & Song, L. (2024) · Cancer Medicine · doi:10.1002/cam4.6749 · Cited by 16
Hassani Alimolk, F., McDonald, F. E. J., Asghari‐Jafarabadi, M., Ahmadi, F., Zenoozian, S., Lashkari, M., & Patterson, P. (2024) · Psycho-Oncology · doi:10.1002/pon.6339 · Cited by 13
Tutus, D., Niemitz, M., Plener, P. L., Fegert, J. M., Lehmann, C., Weiss, C., Knaevelsrud, C., Biehl, L., & Rassenhofer, M. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03029-9 · Cited by 19
“The cut-off value is 34 for the short form [32].”
BackgroundLiu, P., Wu, Q., Cheng, Y., Zhuo, Y., Li, Z., Ye, Q., & Yang, Q. (2024) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2024.102586 · Cited by 16
Piarulli, A., Conversano, C., Ciacchini, R., Miniati, M., Marchi, L., Bazzichi, L. M., Gemignani, A., & Orrù, G. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/v8m0d4 · Cited by 12
“RA patients show fatigue, reduced mobility, pain, relational stress, social isolation, and higher disability-related anxiety levels as compared to patients affected by other diseases (48-50).”
Li, B., Lin, X., Chen, S., Qian, Z., Wu, H., Liao, G., Chen, H., Kang, Z., Peng, J., & Liang, G. (2024) · BMC Public Health · doi:10.1186/s12889-024-17969-1 · Cited by 13
“FoP levels vary among patients with different diseases, and even among patients with the same disease, the FoP level can differ depending on the stage and phase of the disease [9, 24].”
BackgroundMethodLiang, Z., Lin, S., Sun, H., Liao, Y., Zhang, M., Chen, C., & Song, H. (2024) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2024.111980 · Cited by 10
Fear of Cancer Progression: Findings From Case Studies and a Nurse-Led Intervention
Reb, A. M., Borneman, T. R., Economou, D. R., Cangin, M. A., Patel, S. K., & Sharpe, L. (2020) · Clinical journal of oncology nursing · doi:10.1188/20.cjon.400-408 · Cited by 12
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript dysfunctional levels of FOP (Herschbach et al., 2010).”
BackgroundBenign or painful? The interpretation of pain and fear of progression in rheumatoid arthritis
Boyse, J. B., Sharpe, L., Richmond, B., Dear, B., Dudeney, J., Sesel, A.-L., & Menzies, R. E. (2024) · Pain · doi:10.1097/j.pain.0000000000003081 · Cited by 11
Lakhiani, A., Cummins, C., Kumar, S., Long, J. E., Arora, V., Balega, J., Broadhead, T., Duncan, T. J., Edmondson, R. J., Fotopoulou, C., et al. (2023) · Cancers · doi:10.3390/cancers16010075 · Cited by 12
“Total scores ranged from 12 to 60; a cut-off of 34 or above indicates a dysfunctional level of fear of progression [31].”
BackgroundKwakkenbos, L., Willems, L. M., van den Hoogen, F. H. J., van Lankveld, W. G. J. M., Beenackers, H., van Helmond, T., Becker, E. S., & van den Ende, C. H. M. (2014) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-014-9414-3 · Cited by 17
“Also, it has been reported that cognitivebehavioural group therapy is effective in reducing fear of progression in patients with cancer (Herschbach et al., 2010b).”
BackgroundMethodResultInfluentialA Literature Review of the Evidence for the Effectiveness of Experiential Psychotherapies
Mullings, B. (2017) · Psychotherapy and Counselling Journal of Australia · doi:10.59158/001c.71181 · Cited by 9
Copingeffektivität und Progredienzangst bei Krebskranken
Dinkel, A., Henrich, G., & Herschbach, P. (2011) · Zeitschrift für Gesundheitspsychologie · doi:10.1026/0943-8149/a000034 · Cited by 14
Self-citationHinz, A., Schulte, T., Mehnert-Theuerkauf, A., Richter, D., Sender, A., Brock, H., Friedrich, M., & Briest, S. (2024) · Healthcare · doi:10.3390/healthcare12040435 · Cited by 13
“Scores of 34 or above indicate dysfunctional levels of FoP [33,34].”
BackgroundYu, X., Wu, Q., Liu, Y., Han, P., Chen, X., & Guo, Q. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1440850 · Cited by 8
Almatkyzy, G., Mojica, C. M., Stroup, A. M., Llanos, A. A. M., O’Malley, D. M., Xu, B., & Tsui, J. (2020) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2020.1844844 · Cited by 10
Bugaj, T. J., Maatouk, I., Hanslmeier, T., Zschäbitz, S., Huber, J. C., Flock, C., Friederich, H., & Ihrig, A. (2023) · World Journal of Urology · doi:10.1007/s00345-023-04325-y · Cited by 9
“Fear of progression (FoP) is defined as an appropriate anxiousness regarding the progression or recurrence of a disease [8].”
BackgroundPutting Evidence Into Practice: Evidence-Based Interventions for Depression
Fulcher, C. D., Kim, H., Smith, P. R., & Sherner, T. L. (2014) · Clinical journal of oncology nursing · doi:10.1188/14.cjon.s3.26-37 · Cited by 10
Brach, M., Sabariego, C., Herschbach, P., Berg, P., Engst-Hastreiter, U., & Stucki, G. (2010) · Journal of Public Health · doi:10.1093/pubmed/fdq022 · Cited by 9
Self-citationWu, V. S., Smith, A. B., Russell, H., Bamgboje‐Ayodele, A., Beatty, L., Pearce, A. M., Dhillon, H. M., Shaw, J., Antony, J., Fardell, J. E., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13639-6 · Cited by 9
“Clinically significant change was determined as a change in clinical category post-intervention according to FCRI-SF and FoP-Q-SF cut-offs [47, 48].”
Interdisziplinäre Psychoedukation für Hirntumorpatienten und deren Angehörige
Schratter-Sehn, A. U., Schipke, C. S., Steffal, C., & Schratter, A. (2011) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-011-0871-0 · Cited by 7
Li, J., He, Y., Xie, F., Kang, Z., Mei, J., & Mei, B. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07242-z · Cited by 7
“The total score ranges from 12 to 60, with higher overall scores suggesting a greater level of FoP and scores ≥ 34 indicating the clinically dysfunctional level of FoP [49].”
Metadata
- Authors
- Herschbach, P., Berg, P., Waadt, S., Duran, G., Engst-Hastreiter, U., Henrich, G., Book, K., & Dinkel, A.
- Affiliations
- TUM Klinikum (DE)
- IFT Institut für Therapieforschung (DE)
- Schön Klinik Bad Aibling (DE)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2009-11-04
- Volume
- 79
- Issue
- 1
- Pages
- 31-38
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2002637335
- Cited by
- 161
- References
- 50
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 19 · 2023: 10 · 2022: 7 · 2021: 11 · 2020: 14 · 2019: 7 · 2018: 5 · 2017: 8 · 2016: 3 · 2015: 5 · 2014: 9 · 2013: 7 · 2012: 8
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- Bundesministerium für Bildung und Forschung
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- fear of progression, group therapy, cognitive behavioral therapy, chronic arthritis, cancer patients, anxiety, depression, quality of life
- MeSH terms
- Anxiety Disorders, Arthritis, Rheumatoid, Chronic Disease, Depressive Disorder, Fear, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasms, Psychotherapy, Group, Quality of Life
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.